Somewhat Positive News Coverage Somewhat Unlikely to Impact Celyad SA (CYAD) Stock Price
Headlines about Celyad SA (NASDAQ:CYAD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celyad SA earned a news impact score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.9669186276718 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Piper Jaffray Companies reissued a “buy” rating and issued a $49.00 target price (up from $35.00) on shares of Celyad SA in a research report on Friday, September 1st.
Celyad SA (NASDAQ:CYAD) opened at $44.29 on Friday. Celyad SA has a 12-month low of $16.73 and a 12-month high of $64.75.
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.
Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.